Your oncologist used the words cisplatin and pemetrexed. They wrote them down on a yellow notepad. They explained that this is the standard chemotherapy combination for mesothelioma. You have heard the word chemotherapy your whole life. You have never had to know what it actually does. Now you do.
This guide explains mesothelioma chemotherapy in plain language. You will learn which drugs are used, what they do inside the body, what to expect during infusions, what side effects are common, how chemotherapy fits with surgery and immunotherapy, and what newer combinations are emerging. The information will not eliminate the difficulty of treatment, but it will help you walk in prepared.
The Standard First-Line Combination
For more than two decades, the standard first-line chemotherapy for mesothelioma has been a combination of two drugs: cisplatin and pemetrexed. Pemetrexed is sold under the brand name Alimta. The combination was approved specifically for mesothelioma after a major clinical trial in the early 2000s showed it improved survival compared to cisplatin alone. It remains the backbone of chemotherapy for the disease.
Carboplatin is sometimes substituted for cisplatin in patients who cannot tolerate cisplatin’s side effects, particularly those with kidney function concerns or those over a certain age. The carboplatin-pemetrexed combination produces similar response rates with a different side effect profile, generally easier on the kidneys but harder on the bone marrow.
How the Drugs Work
Cisplatin is a platinum-based drug that damages cancer cell DNA, preventing the cells from dividing. The damage triggers cell death pathways inside the cancer cell. Cisplatin works on multiple cancer types and has been a cornerstone of cancer treatment for decades. Its limitation is the collateral damage to healthy cells, particularly in the kidneys, the inner ear, and nerve tissue.
Pemetrexed works differently. It blocks several enzymes that cells need to make DNA building blocks. Without these building blocks, cells cannot divide. Pemetrexed is particularly effective against mesothelioma, lung adenocarcinoma, and certain other cancers. It is generally well tolerated, though it can suppress bone marrow function and cause fatigue.
Together, the two drugs attack cancer cells through different mechanisms simultaneously. The combination is more effective than either drug alone. The combination is also harder on the body than either drug alone, which is the trade-off.
The Treatment Schedule
Mesothelioma chemotherapy is typically delivered in three-week cycles. On day one of each cycle, you come to the infusion centre and receive both drugs intravenously. The infusion takes several hours total, including the pre-medications, the drugs themselves, and the post-infusion fluids. You then have approximately two weeks of recovery before the next cycle begins. Most mesothelioma treatment protocols deliver four to six cycles initially.
You will start a folic acid supplement and receive a vitamin B12 injection before your first cycle. These supplements reduce certain toxicities of pemetrexed. Continue them throughout treatment. Skipping them increases your risk of mouth sores, low blood counts, and other side effects.
Before each cycle, blood work is drawn to verify your blood counts and kidney function are adequate. If they are not, the cycle is delayed by a week to allow recovery. Delays are common and not a failure. The body’s response to chemotherapy is individual, and the schedule adjusts to your specific tolerance.
What Side Effects to Expect
Side effects vary from patient to patient and from cycle to cycle. The most common include nausea, fatigue, decreased appetite, mouth sores, hair thinning rather than complete loss, low blood counts, kidney function changes, peripheral neuropathy, and ringing in the ears. Most are temporary and resolve between cycles or after treatment ends. Some, like peripheral neuropathy from cisplatin, can persist for months or longer after treatment.
Modern anti-nausea medications have transformed the chemotherapy experience. The brutal vomiting of older protocols is largely a thing of the past for most patients. Pre-medications including dexamethasone and several anti-nausea drugs are routinely given before chemotherapy. Take them as prescribed. They work better when given preventively than when used to rescue established nausea.
Fatigue is the side effect that most patients find hardest to manage. It is not just being tired. It is a deep, bone-level exhaustion that does not respond to sleep. The pattern is usually predictable, with the worst fatigue in the days following each infusion and gradual recovery before the next cycle. Plan your schedule around it. Move important commitments to the better days. Allow rest on the harder days without guilt.
Chemotherapy Combined With Surgery
Chemotherapy is often combined with surgical mesothelioma treatment. The combination can take three forms. Neoadjuvant chemotherapy is given before surgery to shrink the tumour and improve the surgical result. Adjuvant chemotherapy is given after surgery to kill remaining microscopic disease. And combined neoadjuvant-adjuvant approaches use chemotherapy both before and after surgery for maximum effect.
Which approach is best depends on the patient’s tumour, fitness, and surgical plan. The decision is made by a multidisciplinary team that includes thoracic surgery, medical oncology, and radiation oncology. Most major mesothelioma treatment centers hold weekly tumour board meetings where these decisions are made collaboratively.
Chemotherapy Combined With Immunotherapy
The newest standard for some mesothelioma patients combines chemotherapy with immunotherapy. The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was approved as a first-line treatment for unresectable pleural mesothelioma in 2020 and showed survival benefit over chemotherapy alone. Some protocols now combine all three: chemotherapy plus dual immunotherapy.
This is a rapidly evolving area. New approvals and trial results are reshaping standard practice every year. Patients diagnosed today should ask explicitly about the latest combination protocols available at their centre. The first-line treatment that was standard in 2020 is no longer the standard in 2026.
Maintenance Therapy
For some patients who respond well to first-line chemotherapy, maintenance therapy continues after the initial cycles to extend the response. Pemetrexed alone is sometimes used as maintenance. The decision balances the benefits of continued treatment against the cumulative toxicity. Discuss the option explicitly with your oncologist.
Maintenance therapy is not for everyone. Patients with significant side effects from initial chemotherapy may not tolerate continued treatment. Patients with very small residual disease after surgery may not need it. The choice is individual.
When Chemotherapy Stops Working
If first-line chemotherapy stops controlling the disease, second-line options exist. They include re-treating with the same drugs if the response was good and the time off treatment is significant. Switching to other chemotherapy drugs like gemcitabine or vinorelbine. Adding or switching to immunotherapy. Enrolling in a clinical trial of an investigational drug. Each option has trade-offs and your oncologist will guide the choice based on your specific situation.
Chemotherapy resistance is the rule rather than the exception in mesothelioma. The longer-term plan accepts that single drug regimens are unlikely to last forever and that sequencing through multiple lines of therapy is a normal part of long-term treatment. Patients who plan for this from the start tend to be less surprised when transitions occur.
A Practical Closing Word
Mesothelioma chemotherapy is hard. It is also among the most consistently helpful interventions available for the disease. The combination of cisplatin and pemetrexed has produced more long-term survivors than any other single treatment modality outside of selected surgical patients. Newer combinations are extending those results.
If you are about to start chemotherapy, lean on the experience of your oncology team. Ask the questions that come up. Track your side effects in a notebook to share at each visit. Bring a family member or friend to infusions when possible. Take the supportive medications seriously. And give yourself permission to rest when your body needs it. The treatment is doing its work.
This article is for educational purposes and does not replace personalised guidance from a medical oncologist. Treatment decisions should be made with your treating team based on your individual situation.